Avantor, Inc. ($AVTR) Stock Forecast: Up 5.5% Today

What is Avantor, Inc.?

Avantor (AVTR) is a company listed on the NYSE that offers products and services to clients in various sectors such as biopharma, healthcare, education, and government. The company recently made key leadership changes and appointments within its Bioscience & Medtech Products division to drive growth and transformation.

Why is Avantor, Inc. going up?

AVTR stock is up 5.5% on Apr 24, 2026 17:41

• The appointment of Ludovic Brellier as the Executive Vice President, Bioscience & Medtech Products, and Chief Transformation Officer has generated positivity around Avantor, signaling a strategic shift towards improving operational performance and implementing company-wide transformation.
• Analysts predict a return to profitability for Avantor this year post the leadership changes and transformation efforts, which likely bolstered investor confidence and contributed to the stock's upward momentum.
• The forthcoming departure of the current EVP, Benoit Gourdier, scheduled by year-end 2026 to assume an integration support role, may be seen as a move to streamline operations and position the company for future growth, further instilling investor optimism in Avantor's potential.
• An investigation into potential corporate misconduct at Avantor before March 5, 2024, initiated by Bronstein, Gewirtz & Grossman, LLC, could have sparked shareholder concerns initially. However, the positive leadership developments and growth strategies appear to have outweighed these apprehensions, driving the bullish market performance.

AVTR Price Chart

AVTR Technical Analysis

AVTR News

Avantor Appoints New Executive VP and Transformation Leader

Avantor (AVTR) announced a leadership change with Executive Vice President Benoit Gourdier transitioning to an integration support role and departing by year-end 2026. Ludovic Brellier has been appointed as the new Executive Vice President, Bioscience and Medtech Products, and Chief Transformation Officer, effective May 1, 2026, to drive transformation in the company's bioscience and medtech operations. TipRanks' AI Analyst, Spark, rates AVTR as Neutral due to weakening fundamentals, conservative 2026 guidance, and negative technicals, although consistent positive cash flow offers support.

https://www.tipranks.com/news/company-announcements/avantor-appoints-new-executive-vp-and-transformation-leader

Avantor names Ludovic Brellier as EVP and transformation officer By Investing.com

Avantor, Inc. (NYSE:AVTR) has appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1. Brellier will oversee the BMP business and lead company-wide transformation initiatives, joining from Danaher where he led Cytiva's Hardware Solutions business. This strategic hire comes as Avantor's stock is near a 52-week low, with analysts forecasting a return to profitability this year.

https://za.investing.com/news/company-news/avantor-names-ludovic-brellier-as-evp-and-transformation-officer-93CH-4230125

Danaher executive joins Avantor to lead product unit and Revival

Avantor (NYSE: AVTR) has appointed Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) and Chief Transformation Officer, effective May 1, 2026. Brellier, previously from Danaher's Cytiva, will be responsible for growing the BMP business, enhancing operational performance, and leading the company's "Revival Management Office" to drive enterprise-wide transformation. The current BMP leader, Benoit Gourdier, will remain until the end of 2026 to ensure a smooth transition.

https://www.stocktitan.net/news/AVTR/avantor-announces-ludovic-brellier-as-executive-vice-president-r8gqgflw0f8o.html

Avantor (NYSE: AVTR) taps Ludovic Brellier to lead BMP and transformation

Avantor, Inc. (NYSE: AVTR) has announced the appointment of Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products and Chief Transformation Officer, effective May 1, 2026. Brellier will lead growth, operational performance, and transformation initiatives through the Revival Management Office, while current EVP Benoit Gourdier will transition to a supporting role before departing the company by December 31, 2026. This leadership change aims to drive business transformation and integration across Avantor's enterprise.

https://www.stocktitan.net/sec-filings/AVTR/8-k-avantor-inc-reports-material-event-829abf027777.html

Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Avantor, Inc. (NYSE:AVTR) concerning corporate wrongdoing. The firm encourages shareholders who purchased Avantor securities prior to March 5, 2024, and continue to hold them, to contact them to assist with the investigation. The representation for investors is on a contingency fee basis.

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/avantor-inc.-avtr-investigation-bronstein-gewirtz-and-grossman-l-1155341

Trending Today

Wheat ($WHEAT) Commodity Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 5.1% Today

Avantor, Inc. Price History

15.00.2026 - AVTR Stock was down 6.3%

• The decrease in Avantor's stock price might be linked to Pacific Capital Partners Ltd's substantial sell-off, resulting in a 22.5% reduction in its holdings.
• Despite recent insider purchases and significant institutional ownership, the decrease in Pacific Capital Partners Ltd's position could have influenced negative market sentiment.
• The anticipation surrounding the upcoming earnings announcement for the fourth quarter and full year of 2025 may be prompting investors to reassess their positions, contributing to the bearish trend.
• Falling slightly short of the quarterly EPS and revenue targets could also have played a role in adding downward pressure on the stock.

29.00.2026 - AVTR Stock was down 5.2%

• The bearish movement in AVTR's stock price today can be attributed to several factors:
• Allegations of misrepresentation and increased competition leading to a federal securities lawsuit may have raised concerns among investors, impacting the stock negatively.
• Insider purchases by Sector Gamma AS and two directors, while initially positive, were overshadowed by Avantor missing its quarterly EPS estimates and providing lower-than-expected guidance for FY2025.
• The upcoming release of Q4 and full-year 2025 financial results, along with discussions on the outlook for 2026, has likely created uncertainty and caution among investors, contributing to the bearish sentiment.
• The ongoing investigations by multiple law firms into potential breaches of fiduciary duties by Avantor's officers and directors have added to the negative sentiment surrounding the stock, further pressuring its price downwards.

21.03.2026 - AVTR Stock was up 5.0%

• The bullish movement in AVTR's stock can be attributed to the company's strategic decision to localize advanced microbial and stability testing at its St. Louis manufacturing site, aiming to streamline supply chain operations and improve turnaround times for biopharma customers.
• Strong near and mid-term sentiment, along with specific AI-generated trading strategies emphasizing a favorable risk-reward setup, likely attracted investors looking for short to mid-term gains.
• AVTR's expansion of quality control capabilities to accelerate biopharma manufacturing, coupled with its emphasis on recurring revenue from consumables and operational efficiencies, reinforces investor confidence in the company's growth potential and market position.
• Despite the ongoing securities investigation by a law firm, the positive market sentiment surrounding AVTR's strategic initiatives and market leadership in life sciences appears to have overshadowed concerns, driving the bullish movement in the stock.

06.02.2026 - AVTR Stock was down 6.1%

• An "underweight" rating on Avantor reiterated by Barclays reflects concerns about future earnings, despite the company surpassing recent earnings expectations slightly. This negative sentiment from analysts may have influenced the stock's bearish movement.
• The negative forecast for Avantor's Q1 2026 earnings by Zacks Research, along with multiple analysts lowering price targets, has added pressure on the stock.
• Despite a high institutional ownership, the significant decrease in stake by the Teachers Retirement System of The State of Kentucky might suggest a lack of confidence in Avantor's future prospects, further impacting the stock price negatively.
• Avantor's historical poor earnings performance, continuously missing EPS and revenue estimates, along with ongoing financial challenges such as low return on equity and declining net profit, have likely heightened investor worries and contributed to the stock reaching a new low.

14.00.2026 - AVTR Stock was down 1.1%

• Today, Avantor (AVTR) experienced a strong bearish movement in the stock market, likely influenced by the following factors:
• The announcement of the upcoming release of Avantor's fourth quarter and full-year 2025 financial results may have created uncertainty among investors, leading to a sell-off of shares in anticipation of the report.
• The partnership with p-Chip Corporation, Choice One Rx, and RxERP to launch a trial demonstrating digital traceability of drug supply chains could have raised concerns about potential costs or challenges associated with implementing new technologies.
• Despite Avantor's CEO presenting at the J.P. Morgan Healthcare Conference and highlighting the company's strategic positioning in the life sciences industry, investors may have focused more on short-term financial performance, contributing to the bearish market movement.

11.01.2026 - AVTR Stock was down 16.5%

• An investigation into potential corporate wrongdoing by Avantor and its officers/directors may have caused concerns among investors, resulting in a sell-off.
• Analysts' expectation of a 2.9% year-over-year revenue decrease in the upcoming earnings report could have influenced the negative sentiment towards the stock.
• Bessemer Group Inc.'s significant reduction in its stake in Avantor, Inc. by selling over 7 million shares likely exacerbated the downward pressure on the stock.
• Avantor's history of underperforming in revenue estimates compared to the sector may have prompted investors to approach the stock cautiously, leading to today's bearish movement.

24.03.2026 - AVTR Stock was up 5.5%

• The appointment of Ludovic Brellier as the Executive Vice President, Bioscience & Medtech Products, and Chief Transformation Officer has generated positivity around Avantor, signaling a strategic shift towards improving operational performance and implementing company-wide transformation.
• Analysts predict a return to profitability for Avantor this year post the leadership changes and transformation efforts, which likely bolstered investor confidence and contributed to the stock's upward momentum.
• The forthcoming departure of the current EVP, Benoit Gourdier, scheduled by year-end 2026 to assume an integration support role, may be seen as a move to streamline operations and position the company for future growth, further instilling investor optimism in Avantor's potential.
• An investigation into potential corporate misconduct at Avantor before March 5, 2024, initiated by Bronstein, Gewirtz & Grossman, LLC, could have sparked shareholder concerns initially. However, the positive leadership developments and growth strategies appear to have outweighed these apprehensions, driving the bullish market performance.

28.00.2026 - AVTR Stock was down 5.2%

• Sector Gamma AS increased its stake in Avantor, Inc., and two directors made insider purchases, but the company missed its quarterly EPS estimates and provided lower-than-expected guidance, leading to a consensus "Hold" rating and a decrease in stock value.
• Investors are eagerly awaiting Avantor's Q4 and full-year 2025 financial results, as well as insights into the company's 2026 financial outlook. Uncertainty surrounding these upcoming announcements may have contributed to the bearish market movement.
• Avantor has been recognized as a significant player in lab infrastructure, supplying essential materials for various industries, which presents a positive long-term investment outlook. However, the discrepancy between market expectations and the company's recent performance could have influenced today's bearish trend.

12.01.2026 - AVTR Stock was down 5.2%

• AVTR stock plummeted post-Q4 earnings disclosure due to the conservative 2026 forecast and a Q4 revenue decline.
• The company's "Revival" initiative aimed at enhancing manufacturing, supply chain, and digital platforms did not capture investor interest, resulting in subdued market sentiment and a stock dip.
• An uptick in put options trading, signaling potential higher volatility or downside for AVTR stock, showcases mixed investor sentiment.
• Despite favorable financial performance, including surpassing earnings expectations and a significant insider buy-in, apprehensions regarding future guidance and market conditions contributed to the downward movement in AVTR stock.

23.03.2026 - AVTR Stock was down 8.7%

• Avantor's CEO, Emmanuel Ligner, emphasized the company's potential in the pharmaceutical and life science sectors. However, market sentiment may have been influenced by concerns regarding revenue pressure and margin compression despite positive strategic insights.
• The expansion of Avantor's Masterflex brand to enhance fluid management for bioprocessing was viewed positively. Nevertheless, investor caution may have stemmed from perceived weakness in the company's long-term outlook in technical analysis.
• Introducing advanced microbial and stability testing capabilities at Avantor's St. Louis site to simplify the supply chain and improve turnaround times might have been overlooked amid doubts about the company's capacity to capture outsourcing demand and fortify its financial prospects.
• The indication of a weak long-term outlook for Avantor in a technical analysis report could have contributed to the stock's bearish performance today, overshadowing positive developments in the company's strategic initiatives and product portfolio expansions.

12.02.2026 - AVTR Stock was down 5.0%

• The decline in Avantor's stock price may be linked to an ongoing securities investigation, potentially causing concerns among investors regarding the company's integrity.
• Despite recent insider purchases and increased stakes by institutional investors such as Barrow Hanley Mewhinney & Strauss LLC and American Century Companies Inc., the negative impact of the investigation news likely overshadowed these positive events.
• The market sentiment might have been influenced by differing analyst ratings, with an overall "Hold" consensus on Avantor, indicating a lack of strong buy recommendations that could have bolstered investor trust.
• While there was a notable rise in institutional ownership, including significant share acquisitions by WINTON GROUP Ltd, this positive development may have been outweighed by the lingering impact of the ongoing investigation, leading to the stock's bearish trend.

09.03.2026 - AVTR Stock was down 5.7%

• The decline in AVTR's stock may be linked to profit-taking by investors post the company's Q1 earnings meeting expectations. Although meeting projections, investors hoped for more robust performance.
• Insider trading activity by the SVP & Chief Accounting Officer, considered as a compensation grant, could have sparked investor concerns regarding the company's future prospects or internal matters.
• The uncertainty surrounding the upcoming earnings report on April 29, 2026, may be fostering caution among traders, contributing to AVTR's stock's downward trend.
• Comparisons with competitors regarding financial health and efficiency metrics might be impacting investor sentiment and influencing AVTR's stock's bearish movement.